Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$15.24 +2.7%	$16.38	$12.72 ▼ $34.47	$2.59B	0.66	1.35 million shs	1.40 million shs
KYMR Kymera Therapeutics	$44.10 +3.5%	$44.17	$19.44 ▼ $53.27	$3.05B	2.18	660,761 shs	508,269 shs
OXBDF Oxford BioMedica	$7.35 +9.2%	$5.30	$3.15 ▼ $7.35	$778.82M	1.08	960 shs	570 shs
RARE Ultragenyx Pharmaceutical	$29.78 +0.9%	$31.69	$25.81 ▼ $60.37	$2.84B	0.25	1.72 million shs	1.27 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	+0.13%	-2.37%	-17.28%	+2.63%	-54.28%
KYMR Kymera Therapeutics	+0.57%	+2.50%	-6.93%	+44.42%	-12.28%
OXBDF Oxford BioMedica	+9.21%	+17.41%	+42.17%	+87.18%	+57.22%
RARE Ultragenyx Pharmaceutical	+0.54%	+1.76%	+11.65%	-17.22%	-48.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	3.1738 of 5 stars	4.4	2.0	0.0	0.0	3.3	1.7	0.0
KYMR Kymera Therapeutics	3.0894 of 5 stars	4.6	1.0	0.0	0.0	2.6	2.5	0.0
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	4.7233 of 5 stars	4.5	3.0	0.0	3.8	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.83	Moderate Buy	$35.20	130.97% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	34.04% Upside
OXBDF Oxford BioMedica	0.00	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$81.50	173.67% Upside

Current Analyst Ratings Breakdown

Latest OXBDF, RARE, KYMR, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$136.00 ➝ $128.00
8/6/2025	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $105.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/28/2025	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$80.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
KYMR Kymera Therapeutics	$47.07M	66.99	N/A	N/A	$13.59 per share	3.25
OXBDF Oxford BioMedica	$111.34M	6.99	N/A	N/A	$1.01 per share	7.28
RARE Ultragenyx Pharmaceutical	$560.23M	5.12	N/A	N/A	$1.57 per share	18.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
OXBDF Oxford BioMedica	-$195.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.53	N/A	N/A	N/A	-87.34%	-237.48%	-37.66%	11/4/2025 (Estimated)

Latest OXBDF, RARE, KYMR, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/5/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	-$1.17	+$0.10	-$1.17	$161.37 million	$166.50 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	12.32	12.32
KYMR Kymera Therapeutics	N/A	8.32	8.32
OXBDF Oxford BioMedica	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	2.45	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
OXBDF Oxford BioMedica	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
OXBDF Oxford BioMedica	N/A
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
OXBDF Oxford BioMedica	891	105.96 million	N/A	Not Optionable
RARE Ultragenyx Pharmaceutical	1,294	96.37 million	91.07 million	Optionable

OXBDF, RARE, KYMR, and IMVT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 22 at 10:00 AM | prnewswire.com

Nuveen LLC Takes $18.78 Million Position in Ultragenyx Pharmaceutical Inc. $RARE

August 22 at 3:47 AM | marketbeat.com

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 21 at 5:00 PM | globenewswire.com

Will Ultragenyx’s (RARE) Rolling FDA Submission for DTX401 Reshape Its Rare Disease Narrative?

August 21 at 3:19 PM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 21 at 2:51 PM | globenewswire.com

Algert Global LLC Grows Position in Ultragenyx Pharmaceutical Inc. $RARE

August 21 at 4:51 AM | marketbeat.com

Aberdeen Group plc Increases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

August 21 at 4:17 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc.: Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of ...

August 19 at 6:58 PM | finanznachrichten.de

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

August 19 at 5:00 AM | marketbeat.com

Invesco Ltd. Reduces Position in Ultragenyx Pharmaceutical Inc. $RARE

August 19 at 4:31 AM | marketbeat.com

Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

August 18, 2025 | globenewswire.com

Connor Clark & Lunn Investment Management Ltd. Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

August 18, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Vanguard Group Inc.

August 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 17, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 16, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 13, 2025 | globenewswire.com

Knott David M Jr Takes $1.74 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

August 12, 2025 | marketbeat.com

Motley Fool Asset Management LLC Grows Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

August 12, 2025 | marketbeat.com

Natixis Advisors LLC Sells 27,404 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

August 12, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 11, 2025 | prnewswire.com

Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143

August 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OXBDF, RARE, KYMR, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$15.24 +0.40 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$15.26 +0.02 (+0.10%)

As of 06:26 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$44.10 +1.51 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$43.54 -0.56 (-1.26%)

As of 07:51 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Oxford BioMedica OTCMKTS:OXBDF

$7.35 +0.62 (+9.21%)

As of 08/21/2025 11:27 AM Eastern

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Ultragenyx Pharmaceutical NASDAQ:RARE

$29.78 +0.26 (+0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$29.90 +0.13 (+0.42%)

As of 07:08 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time